QIAGEN N.V. and Oxford Immunotec Ltd. announced that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston alleging patent infringement in relation to QIAGEN’s QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products.
Under terms of the agreement, all pending claims between Oxford and QIAGEN and the co-defendants have been resolved. As part of the settlement, Oxford has granted QIAGEN a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million. The settlement includes general releases of all parties with no admissions of wrongdoing.
This agreement does not affect QIAGEN's adjusted EPS outlook for the fourth quarter and full-year 2017 since these one-time costs are excluded from adjusted results.